- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
Programmed cell death protein 1 (PD-1) is an inhibitory receptor that is expressed on some tumor cells and causes down regulation of the immune system by reducing T-cell activity. PD-1 inhibitors are a group of proteins that block the activity of PD-1 and PDL1 immune checkpoint.
According to our latest study, the global PD-1 and PD-L1 Inhibitors market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global PD-1 and PD-L1 Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global PD-1 and PD-L1 Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Kg), 2018-2029
Global PD-1 and PD-L1 Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Kg), 2018-2029
Global PD-1 and PD-L1 Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Kg), 2018-2029
Global PD-1 and PD-L1 Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/Kg), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PD-1 and PD-L1 Inhibitors
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PD-1 and PD-L1 Inhibitors market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Novartis, Bristol-Myers Squibb, GlaxoSmithKline and Regeneron Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
PD-1 and PD-L1 Inhibitors market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Humanized IgG1(Immunoglobulin 1)
Humanized IgG4(Immunoglobulin 5)
Cytokine
Market segment by Application
Oral
Subcutaneous Injection
Major players covered
Merck
Novartis
Bristol-Myers Squibb
GlaxoSmithKline
Regeneron Pharmaceuticals
Eli Lilly and Company
Roche Genetech
AstraZeneca
Jiangsu HengRui Medicine Co., Ltd.
Curis Inc.
Aurigene
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PD-1 and PD-L1 Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PD-1 and PD-L1 Inhibitors, with price, sales, revenue and global market share of PD-1 and PD-L1 Inhibitors from 2018 to 2023.
Chapter 3, the PD-1 and PD-L1 Inhibitors competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PD-1 and PD-L1 Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and PD-1 and PD-L1 Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of PD-1 and PD-L1 Inhibitors.
Chapter 14 and 15, to describe PD-1 and PD-L1 Inhibitors sales channel, distributors, customers, research findings and conclusion.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of PD-1 and PD-L1 Inhibitors
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global PD-1 and PD-L1 Inhibitors Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Humanized IgG1(Immunoglobulin 1)
1.3.3 Humanized IgG4(Immunoglobulin 5)
1.3.4 Cytokine
1.4 Market Analysis by Application
1.4.1 Overview: Global PD-1 and PD-L1 Inhibitors Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Oral
1.4.3 Subcutaneous Injection
1.5 Global PD-1 and PD-L1 Inhibitors Market Size & Forecast
1.5.1 Global PD-1 and PD-L1 Inhibitors Consumption Value (2018 & 2022 & 2029)
1.5.2 Global PD-1 and PD-L1 Inhibitors Sales Quantity (2018-2029)
1.5.3 Global PD-1 and PD-L1 Inhibitors Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck PD-1 and PD-L1 Inhibitors Product and Services
2.1.4 Merck PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Merck Recent Developments/Updates
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis PD-1 and PD-L1 Inhibitors Product and Services
2.2.4 Novartis PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novartis Recent Developments/Updates
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business
2.3.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product and Services
2.3.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Bristol-Myers Squibb Recent Developments/Updates
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business
2.4.3 GlaxoSmithKline PD-1 and PD-L1 Inhibitors Product and Services
2.4.4 GlaxoSmithKline PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 GlaxoSmithKline Recent Developments/Updates
2.5 Regeneron Pharmaceuticals
2.5.1 Regeneron Pharmaceuticals Details
2.5.2 Regeneron Pharmaceuticals Major Business
2.5.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitors Product and Services
2.5.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
2.6 Eli Lilly and Company
2.6.1 Eli Lilly and Company Details
2.6.2 Eli Lilly and Company Major Business
2.6.3 Eli Lilly and Company PD-1 and PD-L1 Inhibitors Product and Services
2.6.4 Eli Lilly and Company PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Eli Lilly and Company Recent Developments/Updates
2.7 Roche Genetech
2.7.1 Roche Genetech Details
2.7.2 Roche Genetech Major Business
2.7.3 Roche Genetech PD-1 and PD-L1 Inhibitors Product and Services
2.7.4 Roche Genetech PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Roche Genetech Recent Developments/Updates
2.8 AstraZeneca
2.8.1 AstraZeneca Details
2.8.2 AstraZeneca Major Business
2.8.3 AstraZeneca PD-1 and PD-L1 Inhibitors Product and Services
2.8.4 AstraZeneca PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 AstraZeneca Recent Developments/Updates
2.9 Jiangsu HengRui Medicine Co., Ltd.
2.9.1 Jiangsu HengRui Medicine Co., Ltd. Details
2.9.2 Jiangsu HengRui Medicine Co., Ltd. Major Business
2.9.3 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PD-L1 Inhibitors Product and Services
2.9.4 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
2.10 Curis Inc.
2.10.1 Curis Inc. Details
2.10.2 Curis Inc. Major Business
2.10.3 Curis Inc. PD-1 and PD-L1 Inhibitors Product and Services
2.10.4 Curis Inc. PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Curis Inc. Recent Developments/Updates
2.11 Aurigene
2.11.1 Aurigene Details
2.11.2 Aurigene Major Business
2.11.3 Aurigene PD-1 and PD-L1 Inhibitors Product and Services
2.11.4 Aurigene PD-1 and PD-L1 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Aurigene Recent Developments/Updates
3 Competitive Environment: PD-1 and PD-L1 Inhibitors by Manufacturer
3.1 Global PD-1 and PD-L1 Inhibitors Sales Quantity by Manufacturer (2018-2023)
3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturer (2018-2023)
3.3 Global PD-1 and PD-L1 Inhibitors Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of PD-1 and PD-L1 Inhibitors by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 PD-1 and PD-L1 Inhibitors Manufacturer Market Share in 2022
3.4.2 Top 6 PD-1 and PD-L1 Inhibitors Manufacturer Market Share in 2022
3.5 PD-1 and PD-L1 Inhibitors Market: Overall Company Footprint Analysis
3.5.1 PD-1 and PD-L1 Inhibitors Market: Region Footprint
3.5.2 PD-1 and PD-L1 Inhibitors Market: Company Product Type Footprint
3.5.3 PD-1 and PD-L1 Inhibitors Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global PD-1 and PD-L1 Inhibitors Market Size by Region
4.1.1 Global PD-1 and PD-L1 Inhibitors Sales Quantity by Region (2018-2029)
4.1.2 Global PD-1 and PD-L1 Inhibitors Consumption Value by Region (2018-2029)
4.1.3 Global PD-1 and PD-L1 Inhibitors Average Price by Region (2018-2029)
4.2 North America PD-1 and PD-L1 Inhibitors Consumption Value (2018-2029)
4.3 Europe PD-1 and PD-L1 Inhibitors Consumption Value (2018-2029)
4.4 Asia-Pacific PD-1 and PD-L1 Inhibitors Consumption Value (2018-2029)
4.5 South America PD-1 and PD-L1 Inhibitors Consumption Value (2018-2029)
4.6 Middle East and Africa PD-1 and PD-L1 Inhibitors Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2018-2029)
5.2 Global PD-1 and PD-L1 Inhibitors Consumption Value by Type (2018-2029)
5.3 Global PD-1 and PD-L1 Inhibitors Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2018-2029)
6.2 Global PD-1 and PD-L1 Inhibitors Consumption Value by Application (2018-2029)
6.3 Global PD-1 and PD-L1 Inhibitors Average Price by Application (2018-2029)
7 North America
7.1 North America PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2018-2029)
7.2 North America PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2018-2029)
7.3 North America PD-1 and PD-L1 Inhibitors Market Size by Country
7.3.1 North America PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2018-2029)
7.3.2 North America PD-1 and PD-L1 Inhibitors Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2018-2029)
8.2 Europe PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2018-2029)
8.3 Europe PD-1 and PD-L1 Inhibitors Market Size by Country
8.3.1 Europe PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2018-2029)
8.3.2 Europe PD-1 and PD-L1 Inhibitors Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific PD-1 and PD-L1 Inhibitors Market Size by Region
9.3.1 Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific PD-1 and PD-L1 Inhibitors Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2018-2029)
10.2 South America PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2018-2029)
10.3 South America PD-1 and PD-L1 Inhibitors Market Size by Country
10.3.1 South America PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2018-2029)
10.3.2 South America PD-1 and PD-L1 Inhibitors Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa PD-1 and PD-L1 Inhibitors Market Size by Country
11.3.1 Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa PD-1 and PD-L1 Inhibitors Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 PD-1 and PD-L1 Inhibitors Market Drivers
12.2 PD-1 and PD-L1 Inhibitors Market Restraints
12.3 PD-1 and PD-L1 Inhibitors Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of PD-1 and PD-L1 Inhibitors and Key Manufacturers
13.2 Manufacturing Costs Percentage of PD-1 and PD-L1 Inhibitors
13.3 PD-1 and PD-L1 Inhibitors Production Process
13.4 PD-1 and PD-L1 Inhibitors Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 PD-1 and PD-L1 Inhibitors Typical Distributors
14.3 PD-1 and PD-L1 Inhibitors Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global PD-1 and PD-L1 Inhibitors Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global PD-1 and PD-L1 Inhibitors Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Merck Basic Information, Manufacturing Base and Competitors
Table 4. Merck Major Business
Table 5. Merck PD-1 and PD-L1 Inhibitors Product and Services
Table 6. Merck PD-1 and PD-L1 Inhibitors Sales Quantity (Tons), Average Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Merck Recent Developments/Updates
Table 8. Novartis Basic Information, Manufacturing Base and Competitors
Table 9. Novartis Major Business
Table 10. Novartis PD-1 and PD-L1 Inhibitors Product and Services
Table 11. Novartis PD-1 and PD-L1 Inhibitors Sales Quantity (Tons), Average Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Novartis Recent Developments/Updates
Table 13. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 14. Bristol-Myers Squibb Major Business
Table 15. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product and Services
Table 16. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales Quantity (Tons), Average Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Bristol-Myers Squibb Recent Developments/Updates
Table 18. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 19. GlaxoSmithKline Major Business
Table 20. GlaxoSmithKline PD-1 and PD-L1 Inhibitors Product and Services
Table 21. GlaxoSmithKline PD-1 and PD-L1 Inhibitors Sales Quantity (Tons), Average Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. GlaxoSmithKline Recent Developments/Updates
Table 23. Regeneron Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 24. Regeneron Pharmaceuticals Major Business
Table 25. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitors Product and Services
Table 26. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitors Sales Quantity (Tons), Average Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Regeneron Pharmaceuticals Recent Developments/Updates
Table 28. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 29. Eli Lilly and Company Major Business
Table 30. Eli Lilly and Company PD-1 and PD-L1 Inhibitors Product and Services
Table 31. Eli Lilly and Company PD-1 and PD-L1 Inhibitors Sales Quantity (Tons), Average Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Eli Lilly and Company Recent Developments/Updates
Table 33. Roche Genetech Basic Information, Manufacturing Base and Competitors
Table 34. Roche Genetech Major Business
Table 35. Roche Genetech PD-1 and PD-L1 Inhibitors Product and Services
Table 36. Roche Genetech PD-1 and PD-L1 Inhibitors Sales Quantity (Tons), Average Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Roche Genetech Recent Developments/Updates
Table 38. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 39. AstraZeneca Major Business
Table 40. AstraZeneca PD-1 and PD-L1 Inhibitors Product and Services
Table 41. AstraZeneca PD-1 and PD-L1 Inhibitors Sales Quantity (Tons), Average Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. AstraZeneca Recent Developments/Updates
Table 43. Jiangsu HengRui Medicine Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 44. Jiangsu HengRui Medicine Co., Ltd. Major Business
Table 45. Jiangsu HengRui Medicine Co., Ltd. PD-1 and PD-L1 Inhibitors Product and Services
Table 46. Jiangsu HengRui Medicine Co., Ltd. PD-1 and PD-L1 Inhibitors Sales Quantity (Tons), Average Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
Table 48. Curis Inc. Basic Information, Manufacturing Base and Competitors
Table 49. Curis Inc. Major Business
Table 50. Curis Inc. PD-1 and PD-L1 Inhibitors Product and Services
Table 51. Curis Inc. PD-1 and PD-L1 Inhibitors Sales Quantity (Tons), Average Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Curis Inc. Recent Developments/Updates
Table 53. Aurigene Basic Information, Manufacturing Base and Competitors
Table 54. Aurigene Major Business
Table 55. Aurigene PD-1 and PD-L1 Inhibitors Product and Services
Table 56. Aurigene PD-1 and PD-L1 Inhibitors Sales Quantity (Tons), Average Price (US$/Kg), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Aurigene Recent Developments/Updates
Table 58. Global PD-1 and PD-L1 Inhibitors Sales Quantity by Manufacturer (2018-2023) & (Tons)
Table 59. Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturer (2018-2023) & (USD Million)
Table 60. Global PD-1 and PD-L1 Inhibitors Average Price by Manufacturer (2018-2023) & (US$/Kg)
Table 61. Market Position of Manufacturers in PD-1 and PD-L1 Inhibitors, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 62. Head Office and PD-1 and PD-L1 Inhibitors Production Site of Key Manufacturer
Table 63. PD-1 and PD-L1 Inhibitors Market: Company Product Type Footprint
Table 64. PD-1 and PD-L1 Inhibitors Market: Company Product Application Footprint
Table 65. PD-1 and PD-L1 Inhibitors New Market Entrants and Barriers to Market Entry
Table 66. PD-1 and PD-L1 Inhibitors Mergers, Acquisition, Agreements, and Collaborations
Table 67. Global PD-1 and PD-L1 Inhibitors Sales Quantity by Region (2018-2023) & (Tons)
Table 68. Global PD-1 and PD-L1 Inhibitors Sales Quantity by Region (2024-2029) & (Tons)
Table 69. Global PD-1 and PD-L1 Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
Table 70. Global PD-1 and PD-L1 Inhibitors Consumption Value by Region (2024-2029) & (USD Million)
Table 71. Global PD-1 and PD-L1 Inhibitors Average Price by Region (2018-2023) & (US$/Kg)
Table 72. Global PD-1 and PD-L1 Inhibitors Average Price by Region (2024-2029) & (US$/Kg)
Table 73. Global PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2018-2023) & (Tons)
Table 74. Global PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2024-2029) & (Tons)
Table 75. Global PD-1 and PD-L1 Inhibitors Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Global PD-1 and PD-L1 Inhibitors Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Global PD-1 and PD-L1 Inhibitors Average Price by Type (2018-2023) & (US$/Kg)
Table 78. Global PD-1 and PD-L1 Inhibitors Average Price by Type (2024-2029) & (US$/Kg)
Table 79. Global PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2018-2023) & (Tons)
Table 80. Global PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2024-2029) & (Tons)
Table 81. Global PD-1 and PD-L1 Inhibitors Consumption Value by Application (2018-2023) & (USD Million)
Table 82. Global PD-1 and PD-L1 Inhibitors Consumption Value by Application (2024-2029) & (USD Million)
Table 83. Global PD-1 and PD-L1 Inhibitors Average Price by Application (2018-2023) & (US$/Kg)
Table 84. Global PD-1 and PD-L1 Inhibitors Average Price by Application (2024-2029) & (US$/Kg)
Table 85. North America PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2018-2023) & (Tons)
Table 86. North America PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2024-2029) & (Tons)
Table 87. North America PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2018-2023) & (Tons)
Table 88. North America PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2024-2029) & (Tons)
Table 89. North America PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2018-2023) & (Tons)
Table 90. North America PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2024-2029) & (Tons)
Table 91. North America PD-1 and PD-L1 Inhibitors Consumption Value by Country (2018-2023) & (USD Million)
Table 92. North America PD-1 and PD-L1 Inhibitors Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Europe PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2018-2023) & (Tons)
Table 94. Europe PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2024-2029) & (Tons)
Table 95. Europe PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2018-2023) & (Tons)
Table 96. Europe PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2024-2029) & (Tons)
Table 97. Europe PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2018-2023) & (Tons)
Table 98. Europe PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2024-2029) & (Tons)
Table 99. Europe PD-1 and PD-L1 Inhibitors Consumption Value by Country (2018-2023) & (USD Million)
Table 100. Europe PD-1 and PD-L1 Inhibitors Consumption Value by Country (2024-2029) & (USD Million)
Table 101. Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2018-2023) & (Tons)
Table 102. Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2024-2029) & (Tons)
Table 103. Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2018-2023) & (Tons)
Table 104. Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2024-2029) & (Tons)
Table 105. Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity by Region (2018-2023) & (Tons)
Table 106. Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity by Region (2024-2029) & (Tons)
Table 107. Asia-Pacific PD-1 and PD-L1 Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
Table 108. Asia-Pacific PD-1 and PD-L1 Inhibitors Consumption Value by Region (2024-2029) & (USD Million)
Table 109. South America PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2018-2023) & (Tons)
Table 110. South America PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2024-2029) & (Tons)
Table 111. South America PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2018-2023) & (Tons)
Table 112. South America PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2024-2029) & (Tons)
Table 113. South America PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2018-2023) & (Tons)
Table 114. South America PD-1 and PD-L1 Inhibitors Sales Quantity by Country (2024-2029) & (Tons)
Table 115. South America PD-1 and PD-L1 Inhibitors Consumption Value by Country (2018-2023) & (USD Million)
Table 116. South America PD-1 and PD-L1 Inhibitors Consumption Value by Country (2024-2029) & (USD Million)
Table 117. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2018-2023) & (Tons)
Table 118. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity by Type (2024-2029) & (Tons)
Table 119. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2018-2023) & (Tons)
Table 120. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity by Application (2024-2029) & (Tons)
Table 121. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity by Region (2018-2023) & (Tons)
Table 122. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity by Region (2024-2029) & (Tons)
Table 123. Middle East & Africa PD-1 and PD-L1 Inhibitors Consumption Value by Region (2018-2023) & (USD Million)
Table 124. Middle East & Africa PD-1 and PD-L1 Inhibitors Consumption Value by Region (2024-2029) & (USD Million)
Table 125. PD-1 and PD-L1 Inhibitors Raw Material
Table 126. Key Manufacturers of PD-1 and PD-L1 Inhibitors Raw Materials
Table 127. PD-1 and PD-L1 Inhibitors Typical Distributors
Table 128. PD-1 and PD-L1 Inhibitors Typical Customers
List of Figures
Figure 1. PD-1 and PD-L1 Inhibitors Picture
Figure 2. Global PD-1 and PD-L1 Inhibitors Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global PD-1 and PD-L1 Inhibitors Consumption Value Market Share by Type in 2022
Figure 4. Humanized IgG1(Immunoglobulin 1) Examples
Figure 5. Humanized IgG4(Immunoglobulin 5) Examples
Figure 6. Cytokine Examples
Figure 7. Global PD-1 and PD-L1 Inhibitors Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global PD-1 and PD-L1 Inhibitors Consumption Value Market Share by Application in 2022
Figure 9. Oral Examples
Figure 10. Subcutaneous Injection Examples
Figure 11. Global PD-1 and PD-L1 Inhibitors Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global PD-1 and PD-L1 Inhibitors Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global PD-1 and PD-L1 Inhibitors Sales Quantity (2018-2029) & (Tons)
Figure 14. Global PD-1 and PD-L1 Inhibitors Average Price (2018-2029) & (US$/Kg)
Figure 15. Global PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global PD-1 and PD-L1 Inhibitors Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of PD-1 and PD-L1 Inhibitors by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 PD-1 and PD-L1 Inhibitors Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 PD-1 and PD-L1 Inhibitors Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global PD-1 and PD-L1 Inhibitors Consumption Value Market Share by Region (2018-2029)
Figure 22. North America PD-1 and PD-L1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe PD-1 and PD-L1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific PD-1 and PD-L1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 25. South America PD-1 and PD-L1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa PD-1 and PD-L1 Inhibitors Consumption Value (2018-2029) & (USD Million)
Figure 27. Global PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global PD-1 and PD-L1 Inhibitors Consumption Value Market Share by Type (2018-2029)
Figure 29. Global PD-1 and PD-L1 Inhibitors Average Price by Type (2018-2029) & (US$/Kg)
Figure 30. Global PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global PD-1 and PD-L1 Inhibitors Consumption Value Market Share by Application (2018-2029)
Figure 32. Global PD-1 and PD-L1 Inhibitors Average Price by Application (2018-2029) & (US$/Kg)
Figure 33. North America PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America PD-1 and PD-L1 Inhibitors Consumption Value Market Share by Country (2018-2029)
Figure 37. United States PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe PD-1 and PD-L1 Inhibitors Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific PD-1 and PD-L1 Inhibitors Consumption Value Market Share by Region (2018-2029)
Figure 53. China PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America PD-1 and PD-L1 Inhibitors Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa PD-1 and PD-L1 Inhibitors Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa PD-1 and PD-L1 Inhibitors Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. PD-1 and PD-L1 Inhibitors Market Drivers
Figure 74. PD-1 and PD-L1 Inhibitors Market Restraints
Figure 75. PD-1 and PD-L1 Inhibitors Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of PD-1 and PD-L1 Inhibitors in 2022
Figure 78. Manufacturing Process Analysis of PD-1 and PD-L1 Inhibitors
Figure 79. PD-1 and PD-L1 Inhibitors Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
